Prelude Therapeutics Inc (PRLD)

May 19, 2026

New PROTACs reported in Prelude Therapeutics patent - BioWorld News

May 19, 2026

May 17, 2026

Prelude Therapeutics Incorporated (NASDAQ:PRLD) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates - Sahm

May 17, 2026

May 16, 2026

Earnings Beat: Prelude Therapeutics Incorporated (NASDAQ:PRLD) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts - Yahoo Finance

May 16, 2026

May 15, 2026

Goldman Sachs initiates Prelude Therapeutics stock coverage as Early-Stage Biotech - Investing.com India

May 15, 2026

May 13, 2026

Prelude Therapeutics (PRLD) Losses Narrow In Q1 2026 Challenging Bearish Narratives - Sahm

May 13, 2026

May 12, 2026

TradingKey - TradingKey

May 12, 2026

May 12, 2026

Jefferies raises Prelude Therapeutics stock price target on pipeline progress By Investing.com - Investing.com Australia

May 12, 2026

May 12, 2026

Prelude (PRLD) Reports Progress on Strategic Initiatives and Cas - GuruFocus

May 12, 2026

May 12, 2026

Prelude Therapeutics Reports Q1 2026 Results, Advances Precision Oncology Pipeline and Extends Cash Runway to 2028 - Minichart

May 12, 2026

May 12, 2026

Prelude Therapeutics (NASDAQ:PRLD) Reports Narrower Quarterly Loss, Shares Rise on Cash Runway Extension - ChartMill

May 12, 2026

May 12, 2026

Prelude Therapeutics Inc 1Q 2026: Revenue $4.58M, EPS $(0.13) — 10-Q Summary - TradingView

May 12, 2026

May 12, 2026

Prelude Therapeutics Initiates Phase 1 Study of PRT12396 and Provides R&D Pipeline Update - Quiver Quantitative

May 12, 2026

May 12, 2026

Prelude Therapeutics Q1 net loss narrows as expenses fall - TradingView

May 12, 2026

May 12, 2026

Prelude Therapeutics (NASDAQ: PRLD) trims Q1 2026 loss and extends cash runway to 2028 - Stock Titan

May 12, 2026

May 12, 2026

Prelude Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update - Weekly Voice

May 12, 2026

May 12, 2026

Prelude Therapeutics: Current Cash Runway Into 2Q 2028 >PRLD - Moomoo

May 12, 2026

May 11, 2026

Prelude Therapeutics Is Maintained at Buy by HC Wainwright & Co. - Moomoo

May 11, 2026

May 08, 2026

Wall Street Analysts Think Prelude Therapeutics (PRLD) Could Surge 33.59%: Read This Before Placing a Bet - Yahoo Finance

May 08, 2026

May 08, 2026

Prelude Therapeutics Inc expected to post a loss of 24 cents a shareEarnings Preview - TradingView

May 08, 2026

May 05, 2026

PRLD Initiates Coverage On Prelude Therapeutics -- Price Target Announced at $9.00 - GuruFocus

May 05, 2026

May 04, 2026

D. Boral Capital Initiates Prelude Therapeutics(PRLD.US) With Buy Rating, Announces Target Price $9 - Moomoo

May 04, 2026

May 04, 2026

D Boral Capital initiates coverage of Prelude Therapeutics (PRLD) with buy recommendation - MSN

May 04, 2026

May 03, 2026

Prelude Therapeutics (PRLD) price target increased by 19.35% to 6.29 - MSN

May 03, 2026

May 01, 2026

Prelude Therapeutics (PRLD) Presents Preclinical Data for KAT6A Degarader PRT13722 in Breast Cancer - Yahoo Finance

May 01, 2026

Apr 30, 2026

Prelude Therapeutics (NASDAQ:PRLD) Rating Increased to Hold at Zacks Research - MarketBeat

Apr 30, 2026

Apr 29, 2026

Prelude Therapeutics (NASDAQ: PRLD) outlines 2026 proxy votes on directors, pay and auditor - Stock Titan

Apr 29, 2026

Apr 29, 2026

Short Interest in Prelude Therapeutics Incorporated (NASDAQ:PRLD) Decreases By 22.1% - MarketBeat

Apr 29, 2026

Apr 29, 2026

HC Wainwright Issues Positive Estimate for PRLD Earnings - MarketBeat

Apr 29, 2026

Apr 28, 2026

RA Capital reports 7.88M-share Prelude Therapeutics (PRLD) stake - Stock Titan

Apr 28, 2026

Apr 28, 2026

Prelude Therapeutics (PRLD) Expected to Announce Quarterly Earnings on Tuesday - MarketBeat

Apr 28, 2026

Apr 28, 2026

H.C. Wainwright raises Prelude Therapeutics price target to $8 By Investing.com - Investing.com Canada

Apr 28, 2026

Apr 27, 2026

PRLD Maintained by HC Wainwright & Co. -- Price Target Raised to $8 - GuruFocus

Apr 27, 2026

Apr 27, 2026

HC Wainwright Issues Positive Forecast for Prelude Therapeutics (NASDAQ:PRLD) Stock Price - MarketBeat

Apr 27, 2026

Apr 24, 2026

Thursday’s insider trading: Major buys at Prelude, sells at NuScale - Investing.com

Apr 24, 2026

Apr 23, 2026

Prelude Therapeutics (NASDAQ:PRLD) Director David Bonita Buys 2,815,315 Shares - MarketBeat

Apr 23, 2026

Apr 23, 2026

Prelude Therapeutics (NASDAQ:PRLD) Director Buys $12,499,998.60 in Stock - MarketBeat

Apr 23, 2026

Apr 23, 2026

Insider Purchase: Director at $PRLD Buys 1,689,189 Shares - Moomoo

Apr 23, 2026

Apr 23, 2026

Orbimed entities acquire $12.5m in Prelude Therapeutics stock By Investing.com - Investing.com Canada

Apr 23, 2026

Apr 23, 2026

Prelude Therapeutics director David P. Bonita acquires $12.5 million in stock - Investing.com

Apr 23, 2026

Apr 23, 2026

Prelude Therapeutics director David P. Bonita acquires $12.5 million in stock By Investing.com - Investing.com South Africa

Apr 23, 2026

Apr 23, 2026

Orbimed entities acquire $12.5m in Prelude Therapeutics stock - Investing.com

Apr 23, 2026

Apr 23, 2026

OrbiMed funds add Prelude Therapeutics (PRLD) shares at $4.44 in offering - Stock Titan

Apr 23, 2026

Apr 23, 2026

OrbiMed funds boost Prelude Therapeutics (NASDAQ: PRLD) stake with 2.82M-share buy - Stock Titan

Apr 23, 2026

Apr 21, 2026

Prelude Therapeutics Enters Underwriting for $85.5 Million Equity Offering Led by RA Capital - TradingView

Apr 21, 2026

Apr 20, 2026

Prelude Therapeutics (PRLD) Unveils Promising Preclinical Data f - GuruFocus

Apr 20, 2026

Apr 20, 2026

Prelude Therapeutics (PRLD) Launches $90M Public Offering with S - GuruFocus

Apr 20, 2026

Apr 20, 2026

Prelude Therapeutics Shares Rise on Positive Preclinical Data for Breast Cancer Drug - Moomoo

Apr 20, 2026

Apr 20, 2026

Prelude Therapeutics Unveils Promising Preclinical Data for First-in-Class Oral KAT6A Degrader PRT13722 in HR+/HER2- Breast Cancer at AACR 2026 12 - Minichart

Apr 20, 2026